Ant venom immunotherapy in Australia: the unmet need

2014/07/01 by Raymond J Mullins, Simon G.A. Brown · 2 citations
Medicine · #Food Allergy and Anaphylaxis Research #Allergic Rhinitis and Sensitization #Contact Dermatitis and Allergies #Venom #Anaphylaxis #Tolerability #Allergy #Medicine #Immunotherapy #Immunology #Bee venom #Biology #Pharmacology #Ecology #Adverse effect #Zoology #Immune system

paper · doi:10.5694/mja13.00035

openalex publication_date 2014/07/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south-eastern Australia. The efficacy and real-world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.

Citations

• Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania
• Clinical features and severity grading of anaphylaxis
• Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study
• The natural history of sensitivity to jack jumper ants (Hymenoptera formicidaeMyrmecia pilosula) in Tasmania

Cited by

• Jack jumper ant [wikipedia]
• Myrmecia (ant) [wikipedia]

Related

• Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study
• The Sting Challenge Test: An EAACI Position Paper on Hymenoptera Venom Allergy
• Fatal Anaphylaxis to Indoor Native Fire Ant Stings in an Infant
• Ant venoms
• Recognition, Management, and Prevention of Hymenopteran Stings and Allergic Reactions in Travelers